RECLAIM: Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of cIAI1
As effective as a carbapenem when combined with metronidazole in hospitalised patients with Gram-negative cIAIs1
An international, non-inferiority, randomised, double-blind, comparative, Phase III trial.1
• ZAVICEFTA plus metronidazole versus meropenem
• cIAI requiring surgical intervention or percutaneous draining within 24 hours before or after randomisation
– Randomised patients, N=1066
– mMITT population, N=1043
AE, adverse event; CI, confidence interval; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; mMITT, microbiologically modified intention-to-treat; VAP, ventilator-associated pneumonia.
1. Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9
*The 2 combined studies were sized to provide 90% power for a 10% non-inferiority margin and thus 95% power for a 12.5 non-inferiority margin.
†Patients in the mMITT population are defined as carrying a pathogen at the start of treatment.
Meronem IV 1g – SPC
Legal Category: POM. Basic NHS Cost: 10 vial pack £206.28
Meronem IV 500mg – SPC
Legal Category: POM. Basic NHS Cost: 10 vial pack £103.14
Tazocin 2 g/0.25 g Powder for Solution for Infusion – SPC
Legal category: POM. Basic NHS cost: 1 vial pack £7.65
Tazocin 4 g/0.5 g Powder for Solution for Infusion – SPC
Legal category: POM. Basic NHS cost: 1 vial pack £15.17
Tygacil 50 mg Powder for Solution for Infusion – SPC
Legal Category: POM. Basic NHS Cost: 10 vial pack £323.10
ZAVICEFTA® 2 g/0.5 g Powder for Concentrate for Solution for Infusion – SPC
Legal category: POM. Basic NHS price: 10 vial pack £857.00.
PP-ZVA-GBR-0625. October 2019